A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center

Tag: VTE

  • MTHFR and Homocysteine: Information Handout for Patients

    Stephan Moll, MD writes… A plain language summary for patients and interested public about homocysteine and the MTHFR mutations and their relevance in respect to thrombosis was  published today in the journal Circulation (link here). Reference:  Moll S, Varga EA.  Homocysteine and MTHFR Mutations. Circulation. 2015;132:e6-e.

  • Aspirin Decreases Recurrent DVT and PE

    Stephan Moll, MD writes… Aspirin is beneficial in preventing recurrent venous thromboembolism (VTE) in patients who have had a previous episode of unprovoked VTE and who have been treated with anticoagulant therapy, a publication in the journal Circulation re-confirms this week: Aspirin reduces the risk of recurrent VTE by more than a third without significantly increasing the risk…

  • Commercial Airline Pilots and VTE

    Stephan Moll, MD writes… Interesting study: Are commercial airline pilots at increased risk of venous thromboembolism (VTE) [ref 1]?  One might think so, as air travel is an established, although only weak, risk factor for VTE [ref 2,3].  This study found, however, that the risk of VTE is NOT increased in airline pilots.

  • How Long is the Post-Partum Period in Respect to Thrombosis Risk?

    Stephan Moll, MD writes… A recent NEJM study (ref 1) examined whether the risk for thrombosis in women persists beyond the first 6 weeks after delivery.  It found that an increased risk persists for at least 3 months after delivery, although the absolute risk was low after the first 6 weeks.  This is of clinical…

  • NEJM Publication: Edoxaban for VTE Treatment

    Stephan Moll, MD writes…  Today, Sept 1st, 2013, the New England Journal of Medicine published the phase 3 clinical trial of edoxaban versus warfarin in the treatment of DVT and PE [ref 1]. It showed that edoxaban was as effective as warfarin and led to less clinically relevant bleeding.

  • Aspirin Prevents Recurrent DVT and PE – WARFASA Study

    Stephan Moll, MD writes… A clinically very relevant study (WARFASA) published today (May 24, 2012) in the New England Journal of Medicine [ref 1] shows that aspirin, 100 mg per day, reduces the risk of recurrent venous thromboembolism (VTE) in patients with unprovoked (= idiopathic) VTE, who have completed 6 to 18 months of anticoagulant therapy, without…

  • Psychological impact of DVT and PE

    Beth Waldron, Program Director of Clot Connect, writes… The patient diagnosed with VTE (venous thromboembolism) may develop depression and anxiety, particularly if the clot was extensive and life-threatening.  However, evaluation of the care and outcome of patients with VTE is often focused upon the visible short-term effects of a clot, such as:  Has the acute clotting…

  • VTE Prevention in Hospitalized Patients: New ACP Guideline

    A new guideline was published this week about venous thromboembolism (VTE) prophylaxis in hospitalized medical sick patients and in stroke patients [link here; ref 1]. The key points of this guideline,